These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19878649)

  • 21. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
    Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
    Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
    Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells.
    Mousavi SA; Berge KE; Berg T; Leren TP
    FEBS J; 2011 Aug; 278(16):2938-50. PubMed ID: 21692990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
    Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
    Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function.
    Ramin-Mangata S; Thedrez A; Nativel B; Diotel N; Blanchard V; Wargny M; Aguesse A; Billon-Crossouard S; Vindis C; Le May C; Hulin P; Armanet M; Gmyr V; Pattou F; Croyal M; Meilhac O; Nobécourt E; Cariou B; Lambert G
    Atherosclerosis; 2021 Jun; 326():47-55. PubMed ID: 33933263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.
    Liu M; Wu G; Baysarowich J; Kavana M; Addona GH; Bierilo KK; Mudgett JS; Pavlovic G; Sitlani A; Renger JJ; Hubbard BK; Fisher TS; Zerbinatti CV
    J Lipid Res; 2010 Sep; 51(9):2611-8. PubMed ID: 20453200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9: an enigmatic protease.
    Lopez D
    Biochim Biophys Acta; 2008 Apr; 1781(4):184-91. PubMed ID: 18280815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
    J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection and characterization of human PCSK9 antibody from phage displayed antibody library.
    Cao Y; Yang H; Zhou X; Mao H; Gao T; Hu Z; He L; Pan F; Guo Z
    Biochem Biophys Res Commun; 2015 Aug; 463(4):712-8. PubMed ID: 26056005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells.
    Denis N; Palmer-Smith H; Elisma F; Busuttil A; Wright TG; Bou Khalil M; Prat A; Seidah NG; Chrétien M; Mayne J; Figeys D
    J Proteome Res; 2011 Apr; 10(4):2011-26. PubMed ID: 21332221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells.
    Wang X; Berry E; Hernandez-Anzaldo S; Sun D; Adijiang A; Li L; Zhang D; Fernandez-Patron C
    FEBS Lett; 2015 Feb; 589(4):490-6. PubMed ID: 25613181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.